Navigation Links
AFFiRiS AG: Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board
Date:11/8/2011

us to all parties immediately, that there is a common understanding what the future development of AFFiRiS should look like as we implement the appropriate actions. We are delighted that Santo is appreciating AFFiRiS's potential by committing a substantial stake into the company."

Opportunities > Risks

Regarding his positive investment decision for AFFiRiS, Thomas Strüngmann explains: "We are excited about the opportunity to invest into this very promising biotech company. Seeing what Walter Schmidt and Frank Mattner have created and established with their top class team we remain highly impressed."

A further substantial argument for Santo to invest into AFFiRiS is related to recent developments in its key projects - in particular to the exciting progress of the ongoing Parkinson's project. Here, the aim is to deliver the world's first vaccine for Parkinson's disease - a project for which a Phase I safety and tolerability trial, supported by the American Michael J. Fox Foundation with almost USD 2 million, will start early 2012.The Parkinson's disease vaccine benefits from the company's experience in developing vaccines against Alzheimer's disease. In 2008, the company closed a licence agreement with GSK Biologicals, worth up to EUR 430 Mio. milestone-based payments.  

The basis for all these programmes is the company's AFFITOME® technology plus related know-how which allows the preclinical development of entire vaccine families with high specificity which are then moved quickly into clinical testing following the company's strategy called "clinical maturation".

Michael Motschmann, Management Chairman of the board of MIG Verwaltungs AG, on the most recent company developments: "AFFiRiS is an incredibly attractive investment. The company offers the unique combination of a validated platform technology and an approach of producing several vaccine candidates respectively, for diseases with unmet medical need and attr
'/>"/>

SOURCE AFFiRiS AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
5. AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimers Vaccine Candidate AD02 into Clinical Phase II Testing
6. AFFiRiS AG: Vaccination Against Hypertension is Development Project No. 4 and has Already Been Awarded an FFG Grant of up to EUR 1.2 Million
7. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
8. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
9. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
10. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
11. Aegis Analytical Corp. Showcases Discoverant at Inaugural Venture Capital in the Rockies Fall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Toronto, Canada (PRWEB) July 30, 2014 ... been available in health services research for a ... an upswing in interest regarding the use of ... actual practice conditions. , By combining today’s powerful ... in the digital era, ‘big data’ holds significant ...
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Yuma ... facility and complementary therapies brings comprehensive cancer care ... state-of-the-art Yuma Regional Cancer Center has officially opened. ... the program includes services such as open, semi-private ... therapy, American Cancer Society Resource Center, hematology, rehabilitation ...
(Date:7/30/2014)... --  Epic Sciences, Inc. ("Epic"), a private biotech ... and advance the treatment and management of cancer, announced ... as chairman of Epic,s board of directors. Mr. Lucier ... Invitrogen). Mr. Lucier joins Epic,s board of directors to ... analysis platform with special focus on the development of ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... June 3 Experts from PAREXEL International Corporation (Nasdaq: ... provider, will address important industry issues at the Drug ... June 21 - 25, 2009 in San Diego, California. ... topics ranging from global development strategies, clinical logistics in ...
... ... Adventus EHC ® Enhanced Natural Attenuation Biotechnology as Demonstrably Superior to Alternatives ... New York, NY ... enterprise for treatment of contaminated soil, sediment and groundwater environments, is proud to announce ...
... from their roots up to their leaves hundreds of feet ... the University of Rochester have created a simple slab of ... at a speed that would make nature envious. , The ... Letters , may prove invaluable in pumping microscopic amounts of ...
Cached Biology Technology:PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting 2PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting 3PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting 4PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting 5PAREXEL Experts to Present Leading Insights at Drug Information Association 45th Annual Meeting 6Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy 2Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy 3Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy 4Scientists create metal that pumps liquid uphill 2Scientists create metal that pumps liquid uphill 3
(Date:7/30/2014)... treatment has been shown to relieve patients, pain. ... transmission between the peripheral and central nervous systems, ... Radiation Medicine, Chinese Academy of Medical Sciences, China ... dorsal root ganglia (DRG) to provide relief for ... 14.8, 29.6 MBq) were implanted separately into the ...
(Date:7/30/2014)... cells types. Researchers would like to understand how to channel ... make up the organs and other structures of living organisms. ... sugars that dangle from proteins on surfaces of cells. , ... has created synthetic molecules that can stand in for the ... the process, they report in the Journal of the ...
(Date:7/30/2014)... 2014 The Nano-Bio Manufacturing Consortium (NBMC), ... Force Research Laboratory (AFRL), has awarded funding for ... University to develop electronics and biometric sensor ... project, with contributions from the University of California, ... ( Endicott, N.Y. ), is scheduled ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... University of Colorado Boulder researchers who have adapted a ... time some 2.8 billion years ago when the sun ... have been more prone to catastrophic glaciation than previously ... Eon on Earth that lasted from about 3.8 billion ...
... HEIDELBERG -- EMBO today announces the selection of seven ... The grants will assist the researchers to relocate and ... and Turkey. "The EMBO Installation Grants directly support ... said Gerlind Wallon, Installation Grants Programme Manager and EMBO ...
... In pets and people, the time it takes to diagnose ... of Missouri veterinarian is identifying ways to diagnose pet infections ... resulting test could be used eventually for humans. "Infections ... send samples to a lab and wait three days or ...
Cached Biology News:Early Earth may have been prone to deep freezes, says CU-Boulder study 2Early Earth may have been prone to deep freezes, says CU-Boulder study 3
...
Sterile detoxified 10% bovine serum albumin (BSA) in Iscoves MDM. This BSA has been selected to support the optimal colony growth of human hematopoietic progenitor cells in methylcellulose-based medi...
... full-featured high-performance ICP-MS system designed for flexibility ... Omega II off-axis ion lens, true hyperbolic ... can handle the widest range of sample ... 7500a now includes as standard Agilents unique ...
... DH-2000, except that it uses a deep-UV deuterium ... and comes with a shutter (controlled via a ... The DH-2000 Deuterium Tungsten Halogen Light ... tungsten halogen light sources in a single optical ...
Biology Products: